Cookie Policy         The Babraham Research Campus is also home to The Babraham Institute


  Babraham Bioscience Technologies
        Babraham Research Campus - Cambridge - UK
 

Sponsors

 

MedImmune

 

Neusentis
Babraham Bioscience Technologies Ltd One NucleusCambridge Enterprise

BioInvestment Forum 2014
8th May 2014, Babraham Research Campus, Cambridge

 

Stay Connected INVESTORS

 

Who should attend? Venture, Corporate Capital groups and Business Angels

 

- Hear elevator pitches from early stage companies seeking funding (£250K - £5M)

- Poster board exhibition

- 'On the Sofa' with Andy Richards

- Networking

- Guest speaker Jonathan Milner, Abcam, discusses sector specific issues
- Join like minded investors at the exclusive Investor Dinner hosted by Cambridge Enterprise at Homerton College, Cambridge

 

RegisterRegistration

Attendance at BIF2014 only: £30

Attendance at BIF2014 and the exclusive Investor Dinner: £120

Fees are inclusive of VAT.

 

Companies Confirmed to Present so far

ABeterno Limited - Funding Required £750K

ABeterno has developed IP in using intracellular proteins as the capture targets for isolation of viable whole cells, enabling their subsequent use in downstream applications. We will use this to exploit a new commercial opportunity in the well established markets for cell separation and live cell imaging, reaching profitability within 2 years and generating substantial returns for investors within 4-5 years via a trade sale in a rapidly growing market sector.

 

ARTERIUS - Funding Required £2.95M
The Company plans to develop and introduce a range of biodegradable drug eluting coronary stents. The unique properties of these stents are that once they have caused vessel remodelling and have been encapsulated in the vessel wall, they biodegrade after a period of 12 to 24 months. The development of fully biodegradable stents that perform the necessary function of remodelling the arterial flow area and then disappear, could make a radical contribution to the priority of tackling a disease that is one of the greatest contributors to mortality in the UK and worldwide.

 

DiagNodus Limited - Funding Required £500-700K
DiagNodus develops new diagnostic approaches in the area of colorectal disease and targets inflammatory bowel disease (IBD) and colorectal cancer (CRC). Clinical endpoints comprise disease detection, monitoring, screening and therapy efficiency assessment. The company has successfully devised and clinically tested a new method for non-invasive colorectal sample collection and a family of biomarker-based diagnostic tests. The company is currently initiating the development of a point of care (POC) version of its test for IBD and prepares to start clinical trials targeting CRC.

 

Mantra Bioscience Limited - Funding Required £370K

Healthcare Associated Infections cost the UK around £1bn per year, despite years of investment.  Research shows that ubiquitous healthcare devices such as blood pressure cuffs and pulse oximeters are crucial causes of infection spread, but a reliance on manual cleaning has been totally ineffective.  Mantra Medical’s objective is to change that forever with our unique products that provide rapid and effective bedside decontamination of blood pressure cuffs and pulse oximeters without relying on manual cleaning.  We have solid IP, related concepts in other medical submarkets, and have initial commercial interest from two large established medical companies.      

 

Miti Biosystems - Funding Required £1.5M
Miti Biosystems is harnessing enzymes from nature to generate highly constrained peptides as therapeutics. Lead compounds hold the promise to combine the best of mAbs with traditional small molecules. Miti's polycyclic peptides are called RiPPs (ribosomally synthesised post-translationally modified peptides) and are amenable to phage display and other diversity methods. The unusual structure, stability, thermodynamically disfavoured bond tensions and novel binding mode of RiPPs open up novel chemical space. As many RiPPs have proven oral bioavailability and cell penetration characteristics in nature, we aim to tap this neglected source of drug-like compounds for Pharma & Biotech

 

Nemesis Bioscience Limited - Funding Required £1M
Nemesis Bioscience will develop and commercialise therapeutic agents that will resurrect the antibiotic sensitivity of currently resistant bacterial pathogens. The company will develop these agents as both able to kill pathogenic bacteria and also confer upon them future sensitivity to currently approved antibiotics. This will include, not only the ability to treat life-threatening infections directly, but also to prophylactically administer agents that will prevent the patient acquiring such resistant pathogens in institutional settings. These agents can be delivered by a variety of mechanisms including oral, topical and dietary supplement routes.


Rare Biotech Limited - Funding Required £1.5M
Rare Biotech is targeting rare diseases and the development of orphan drugs.  We identify, evaluate and develop technologies with therapeutic and commercial potential sourced from both academia and industry.  Development plans are matched with appropriate sources of funding to accelerate the progression of technologies through to the clinic.   Rare Biotech operates a ‘virtual company model’ out-sourcing R&D to maximise the impact of funding. A portfolio of technologies are targeted to provide attractive opportunities for future partners and investment.  Rare Biotech was founded in January 2014 and is currently assembling initial technologies and funding.

 

Vasgen Limited - Funding Required £3.5M
Vasgen Ltd is a biotech start-up based in London, developing a novel platform technology to deliver highly selective inhibitors of the metzincin superfamily of metalloproteinases. By targeting antibodies to the enzyme’s catalytic centre, coined AbIMP® technology, Vasgen intends to overcome the historical problem of target non-selectivity and associated side-effects attributed to chemical inhibitors, thereby offering new possibilities for drug discovery and therapy. Our pathfinding programme has developed the world’s first selective pharmacological inhibitor of ADAM15, a validated and previously intractable anti-angiogenesis and anti-tumour target, as a potential novel therapy to capture significant value in the ophthalmology and cancer markets.

 

Veraz - Funding Required £2.6M

Veraz is an innovation led company that has developed novel workflow management and process quality assurance products and techniques. By first quarter 2015 we will be delivering a revolutionary suite of products that protect patients from poor or absent health care. These products rely on our patented sensor technology which detects what/who/where/when people touch. In a clinical trial we monitored staff compliance to their hand hygiene obligations. We measured compliance rates averaging 20% of those being reported. When we provided instant feedback compliance rates rose by 300%. This year we are also adding to the list of care procedures that the products will support, for example, patient repositioning.

 

Travel and Parking

The nearest train station is Cambridge with taxi services available.
Ample free car parking on site.
The Campus has links with local hotels in and around Cambridge. Contact Us for more information.

 

 

 

Babraham Bioscience Technologies Ltd - Cambridge - United Kingdom